

Explanatory Note: The following is a presentation by Option Care Health, Inc. posted to a website hosted at www.optioncarehealthamedisys.com in connection with the proposed merger of Option Care Health, Inc. and Amedisys, Inc.



Disclaimer

No Offer or Solicitation

This communication relates to the proposed merger (the "proposed transaction") between Option Care Health, Inc. ("Option Care Health") and Amedisys, Inc. ("Amedisys"). This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Additional Information and Where to Find It

In connection with the proposed transaction, Option Care Health and Amedisys will file relevant materials with the United States Securities and Exchange Commission (the "SEC"), including an Option Care Health registration statement on Form S-4 that will include a joint proxy statement of Option Care Health and Amedisys that also constitutes a prospectus of Option Care Health, and a definitive joint proxy statement/prospectus will be mailed to stockholders of Option Care Health and Amedisys. INVESTORS AND SECURITY HOLDERS OF OPTION CARE HEALTH AND AMEDISYS ARE URGED TO READ THE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the joint proxy statement/prospectus (when available) and other documents filed with the SEC by Option Care Health or Amedisys through the website maintained by the SEC at <http://www.sec.gov>. Copies of the documents filed with the SEC by Option Care Health will be available free of charge on Option Care Health's internet website at <https://investors.optioncarehealth.com> or by contacting Option Care Health's investor relations department at investor.relations@optioncare.com. Copies of the documents filed with the SEC by Amedisys will be available free of charge on Amedisys' internet website at <https://investors.amedisys.com> or by contacting Amedisys' investor relations department at IR@amedisys.com.

Certain Information Regarding Participants

Option Care Health, Amedisys and their respective directors and executive officers may be considered participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Option Care Health is set forth in its proxy statement for its 2023 annual meeting of stockholders, which was filed with the SEC on April 7, 2023. Information about the directors and executive officers of Amedisys is set forth in its proxy statement for its 2023 annual meeting of stockholders, which was filed with the SEC on April 27, 2023. Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests, by security holdings or otherwise, will be contained in the joint proxy statement/prospectus and other relevant materials to be filed with the SEC regarding the proposed transaction when they become available. You may obtain these documents (when they become available) free of charge through the website maintained by the SEC at <http://www.sec.gov> and from the investor relations departments at Option Care Health or Amedisys as described above.

Cautionary Statement Regarding Forward-Looking Statements

This communication may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "believe," "project," "estimate," "expect," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include projections as to the anticipated benefits of the proposed transaction as well as statements regarding the impact of the proposed transaction on Option Care Health's and Amedisys' business and future financial and operating results, the amount and timing of synergies from the proposed transaction and the closing date for the proposed transaction.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on management's current beliefs, expectations and assumptions regarding the future of Option Care Health's and Amedisys' business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of Option Care Health's and Amedisys' control. Option Care Health's, Amedisys' and the combined company's actual results and financial condition may differ materially from those indicated in the forward-looking statements as a result of various factors. These factors include, among other things, (1) the termination of or occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement or the inability to complete the proposed transaction on the anticipated terms and timetable, (2) the inability to complete the proposed transaction due to the failure to obtain approval of the stockholders of Option Care Health or Amedisys or to satisfy any other condition to closing in a timely manner or at all, or the risk that a regulatory approval that may be required for the proposed transaction is delayed, is not obtained or is obtained subject to conditions that are not anticipated, (3) the ability to recognize the anticipated benefits of the proposed transaction, which may be affected by, among other things, the ability of the combined company to maintain relationships with its patients, payers and providers and retain its management and key employees, (4) the ability of the combined company to achieve the synergies contemplated by the proposed transaction or such synergies taking longer to realize than expected, (5) costs related to the proposed transaction, (6) the ability of the combined company to execute successfully its strategic plans, (7) the ability of the combined company to promptly and effectively integrate the Option Care Health and Amedisys businesses and (8) the diversion of management's time and attention from ordinary course business operations to completion of the proposed transaction and integration matters. The foregoing review of important factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included elsewhere. Additional information concerning risks, uncertainties and assumptions can be found in Option Care Health's and Amedisys' respective filings with the SEC, including the risk factors discussed in Option Care Health's and Amedisys' most recent Annual Reports on Form 10-K, as updated by their Quarterly Reports on Form 10-Q and future filings with the SEC.

It should also be noted that prospective financial information for the combined businesses of Option Care Health and Amedisys is based on management's estimates, assumptions and projections and has not been prepared in conformance with the applicable accounting requirements of Regulation S-X relating to pro forma financial information, and the required pro forma adjustments have not been applied and are not reflected therein. This prospective financial information should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Accordingly, there can be no assurance that the prospective financial information is indicative of the future performance of the combined company or that actual results will not differ materially from those presented in the prospective financial information. Inclusion of the prospective financial information in this communication should not be regarded as a representation by any person that the results contained in the prospective financial information will be achieved. None of this information should be considered in isolation from, or as a substitute for, the historical financial statements of Amedisys and Option Care Health.

Any forward-looking statement made in this communication is based only on information currently available to Option Care Health and Amedisys and speaks only as of the date on which it is made. Option Care Health and Amedisys undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. You are cautioned not to rely on Option Care Health's and Amedisys' forward-looking statements.

Note Regarding Use of Non-GAAP Financial Measures

In addition to the financial measures presented in accordance with U.S. generally accepted accounting principles ("GAAP"), this communication includes certain non-GAAP financial measures, such as Adjusted EBITDA. Option Care Health and Amedisys believe Adjusted EBITDA provides useful supplemental information regarding the performance of their business operations and facilitates comparisons to their historical operating results. Adjusted EBITDA should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of liquidity. In addition, Option Care Health's and Amedisys' definition of Adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. For a definition of Adjusted EBITDA and a full reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, please see Option Care Health's Current Report on Form 8-K filed with the SEC on February 23, 2023 and Amedisys' Current Report on Form 8-K filed with the SEC on February 15, 2023. Adjusted EBITDA for Amedisys as disclosed herein adds back stock-based compensation of \$17 million for full year 2022.

This communication also includes certain financial measures for the combined company. These measures are provided for illustrative purposes, are based on an arithmetic sum of the relevant historical financial positions of Option Care Health and Amedisys and do not reflect pro forma adjustments. These measures do not reflect what the combined company's financial condition or results of operations would have been had the proposed transaction occurred on or prior to the dates indicated. The combined company's actual financial position and results of operations may differ significantly from the amounts reflected herein due to a variety of factors.



Today's Participants



option care health



amedisys



John

Rademacher

Chief Executive Officer



Richard

Ashworth


President and Chief Executive Officer



Mike

Shapiro

Chief Financial Officer



Scott

Ginn

Acting Chief Operating Officer
and Chief Financial Officer



Nick

Muscato

Chief Strategy Officer



option care health



amedisys

Key Transaction Terms








Transaction Structure and Exchange Ratio	<ul style="list-style-type: none"> Option Care to issue shares to Amedisys in an all-stock transaction valued at \$3.6B, including assumption of net debt 3.0213 shares of Option Care to be exchanged for each share of Amedisys —Implies a 26% premium to Amedisys' stock price on May 2nd
Ownership	<ul style="list-style-type: none"> Option Care Health shareholders: 64.5% Amedisys shareholders: 35.5%
Synergies	<ul style="list-style-type: none"> Approximately \$75M¹ in anticipated annual incremental EBITDA from run-rate revenue and net cost synergies by year three following transaction close
Management	<ul style="list-style-type: none"> Chief Executive Officer: John Rademacher Chief Financial Officer: Mike Shapiro Executive team comprised of best talent from both organizations
Board	<ul style="list-style-type: none"> 10 member Board to be comprised of 7 directors from Option Care Health's Board and 3 directors from Amedisys' Board
Name	<ul style="list-style-type: none"> Retain Option Care Health corporate name, common shares to be traded on NASDAQ under ticker symbol OPCH
Leverage	<ul style="list-style-type: none"> Combined Net Leverage of ~2.0x²
Timing / Conditions	<ul style="list-style-type: none"> Subject to approval by Option Care Health and Amedisys stockholders and other customary closing conditions, including receipt of applicable regulatory approvals Transaction expected to close in second half of 2023



¹ Includes anticipated \$50M of net run-rate cost synergies and \$25M of EBITDA impact from revenue synergies.

² Calculated as net debt divided by Adjusted EBITDA on a combined basis for the year ended December 31, 2022. Adjusted EBITDA is a non-GAAP measure. Please see Note Regarding Use of Non-GAAP Financial Measures on slide 2.

Uniting Two Complementary Companies

	 option care health	 amedisys	 +  amedisys	
Financial Metrics	Enterprise Value ¹	\$6.7B	\$3.0B	\$9.7B
	Market Cap ¹	\$5.9B	\$2.5B	\$8.4B
	2022 Revenue	\$3.9B	\$2.2B	\$6.2B⁶
	2022 Adjusted EBITDA ⁴	\$343M	\$279M²	\$622M
	2022 Cash Flow From Operations	\$268M	\$133M	\$401M
Operational Metrics⁵	Patients Served Annually	>265K	>455K	>720K
	Clinical Team Members	4.5K+	12K+	16.5K+
	Service Locations ³	163	511	674
	Payer Mix	 <p>Direct Gov't 12%</p> <p>Commercial 88%</p>	 <p>Direct Gov't 76%</p> <p>Commercial 24%</p>	 <p>Direct Gov't 35%</p> <p>Commercial 65%</p>



Combination Creates a Leading, Independent Platform Across Home and Alternate Site Care Spectrum



¹ As of market close on May 2, 2023. ² Adjusted EBITDA adds back stock-based compensation of \$17M. ³ Service locations defined as pharmacy care management centers, standalone ambulatory infusion suite (AIS) locations, home health care centers, and hospice care centers. ⁴ Adjusted EBITDA is a non-GAAP measure. Please see Note Regarding Use of Non-GAAP Financial Measures on slide 2. ⁵ Excludes Amedisys PCL divestiture. ⁶ Difference due to rounding.

Combination Creates a Leader in Home and Alternate Site Care with Differentiated Scale and Unique Cash Flow Profile...

\$9B+

In Combined Revenue Expected by 2027^{1,2}

>10%

Pro Forma EBITDA Margin

~\$1B

In Combined EBITDA Expected by 2027^{1,2}

\$500M+


In Annual Cash Flow from Operations Expected by 2025

At Least 5%

Accretive to GAAP EPS Expected in 2024^{2,3}



¹ Based on Management's expectations of high single digit revenue growth and low double digit Adjusted EBITDA growth. ² Future Medicare FFS reimbursement rate changes are conservatively included in the model. ³ GAAP EPS includes all integration expenses in 2024 assuming a close in 2023.



...That Is Positioned for Accelerated Growth via Several Significant Tailwinds

Improves Patient Experience

>68%



of patients would shift to a single home health and infusion provider if one existed per discharge planners / care coordinators¹

64%



of care coordinators and discharge planners cite an estimated 60%+ performance improvement via a combined home health and infusion provider for patients transitioning to the home¹

Positions PF Company to Transition Towards Case Rate/Episodic then Risk-Based and Value-Based Care

>66%



of payers expect to enter a new value-based arrangement for post-acute care within three years¹

70%



of payers indicated that they have high interest in combined infusion / home health value-based arrangements¹

Drives Significant Cost Savings

70 – 80%



Reduction in cost by shifting patient care out of SNF and LTAC settings into home¹

\$1 – 3bn



reduction in total SNF post-acute spend across Medicare FFS population via length of stay reductions by transitioning patients effective into the home^{1,2}




+



¹McKinsey, 2023. McKinsey Option Care and Amedisys Value Story. Press search, expert interviews, company annual reports. ² Assumes \$300-400 per day and a 2-5 day average reduction across all patients.

Compelling Strategic Rationale



Transform healthcare through innovative platform that improves outcomes, expands access to care, reduces cost and delivers hope and dignity to patients and their families

Comprehensive Capabilities Across Care Continuum Expands Access to Care and Enhances Growth

>\$100B of combined Total Addressable Market with Additional Whitespace Opportunity¹



Positioned to meet growing demand due to increased therapeutic pathways, aging populations, and growing desire for alternate site health services

Delivers Significant Benefits to Patients by Broadening Stakeholder Relationships



Patient Benefits

- Better outcomes
- Broader access to high-quality care
- Lower cost of care
- More efficient care coordination
- More seamless experience across alternate site services

Deeper Payer Relationships

- Option Care Health and Amedisys have track records of working closely with payers to offer consistent, high-quality care at appropriate cost
- Transaction expected to expand relationships with commercial and government payers


















Single Partner to Health Systems and Providers

- Improved efficiency and greater care coordination with reduced administrative burden
- Access to unique longitudinal data sets drives intelligent insights, which lead to better outcomes and lower cost of care
- Combined company will serve as a single partner across alternate site care spectrum

Enhanced Partnerships with BioPharma

- Broader care model for comprehensive chronic condition management
- Deeper clinical insights through expansive data collection and analysis
- Robust platform to support decentralized clinical trials through post-launch support

Combination's Unique Capability Set Enables Comprehensive Care Across Patient's Care Journey

Patient Scenario	Combined Company Services Provided	Value to Healthcare System
Complex Chronic 	 	 Lowers Cost of Care
Post-Acute 		 Prevents Readmission Rates <small>Avoided EF</small>
Terminal Illness 		 SNF / Facility Avoidance 
SNF @ Home 		 Streamlines Service
Future State New Drug Therapies 		 Enhances Patient Satisfaction



¹ Potential to prevent up to 26% in medication-based hospital readmits (Drug Topics).

² Combined company to optimize the clinical care teams and support them to work at the top of their licenses.

Scaled and Unparalleled Clinician Team Across Broad Professional Specialties...

Unparalleled Clinical Platform...



>16,500
Clinicians

- Social Workers
- Physical Therapists
- Home Health Nurses
- Infusion Nurses
- Dietitians
- Bereavement Counselors
- Speech Therapists
- Nurse Practitioners
- Pharmacy Technicians
- Respiratory Therapists
- Occupational Therapists
- Nurse Aids
- Pharmacists



...With Leading Employer Value Proposition...

...Part of a broader, dedicated team of ~26,000...

- Significant investment in training and development
- Relentless focus on being an employer of choice



...Powered by Recent Investments and Collaborations


...Leveraging technology to unlock clinical productivity and insights nationwide



...and National Platform that Increases Access to High Quality Care

National Footprint with a Local Focus¹

-  Option Care Management Centers
-  Option Care Stand-Alone Infusion Centers
-  Amedisys Home Health Care Centers
-  Amedisys Hospice Care Centers



Enables Intelligent Insights to Enhance Outcomes and Reduced Cost of Care



Real-Time Feedback for Care, Coordination, and Optimization



Enable Value-Based Care Models and Other Insights for Payers



Robust Analytics to Provide Enhanced Insight and Decision Support



Population Analytics



BioPharma Collaboration and Clinical Trial Management Capabilities



Utilize Data to Streamline Patient Care Pathways



Lower Total Cost of Care



Deliver Quality Patient Outcomes




Improve Patient Experience

option care health + amedisys

>720K

Patients Served with Data Aggregation



Builds on Track Records of Delivering High Quality Care and Patient Satisfaction

OPTION CARE HEALTH

92%⁴

Patient Satisfaction

AMEDISYS

4.49¹ ★

Quality of
Patient Care

3.57² ★

Patient
Satisfaction

Consistently above industry average



PCAB Option Care Health was the first home infusion provider nationally to achieve certification at all our clean room locations from the Pharmacy Compounding Accreditation Board (PCAB), demonstrating our leadership and prioritization of safety and quality in compounding pharmacy operations.



Option Care Health has held URAC accreditation since 2017, evidencing commitment to deliver on high standards of care for patients and investments in clinicians and quality oversight programs.



Option Care Health holds accreditation at all pharmacy and ambulatory infusion suites, demonstrating commitment to patient care and high clinical standards.



99% HIS Composite Score
in Hospice



99% Home Health
Centers with 4+ Stars



Accredited for ongoing quality,
growth and compliance



Amedisys holds accreditation at
Home Health and Hospice
agencies, demonstrating
commitment to patient care and
high clinical standards³

Differentiated Quality Positions Combined Company Well for Value Based Arrangements

¹ Maintained the highest Quality of Patient Care star score in the Home Health industry in the Home Health Compare ("HHC") April 2023 preview of 4.49 stars, with 99% of care centers at 4+ Stars and 46 care centers rated at 5 stars. ² Patient Satisfaction star average for January 2023 Home Health industry in the Home Health Compare ("HHC") release was 3.57, outperforming the industry average by 1%. ³ <https://www.amedisys.com/about/why-amedisys/> ⁴ Jan-Dec 2022 patient satisfaction data, survey of 25,918 patients.

Combined Company has Strong Financial Platform with Pathway to Create Significant Value for Shareholders

Differentiated Combined Financial Profile

2022A Revenue **\$6.2B¹**

2022A Adj. EBITDA² **\$622M**

2022A Cash Flow From Operations **\$401M**

Combined Net Leverage **~2.0x³**

With Meaningful Synergy Opportunity⁴

Cost **~\$50M**

- Technology enabled efficiencies to increase productivity
- Optimize geographic footprint
- Realign costs through combined purchasing volumes

Revenue⁵ **~\$25M**

- Enhanced care coordination across respective patient bases
- Pursue new programs and offerings



¹ Difference due to rounding. ² Adjusted EBITDA reflects combined 2022 figures, inclusive of \$343M of Option Care 2022A Adjusted EBITDA and \$279M of Amedisys 2022A Adjusted EBITDA which adds back stock-based compensation of \$17M. Adjusted EBITDA is a non-GAAP measure. Please see Note Regarding Use of Non-GAAP Financial Measures on slide 2. ³ Calculated as net debt divided by Adjusted EBITDA on a combined basis for the year ended December 31, 2022. ⁴ Annual run-rate by year three following close. ⁵ In incremental adjusted EBITDA from revenue synergies.

✓ Substantial synergy potential driven by a leading healthcare services management team with a track record of execution

✓ Substantial scale drives Free Cash Flow generation

✓ Enhanced credit profile with significant capital reserves for flexible shareholder-friendly capital deployment

Combination Provides Visibility into Several Top-Line Synergy Opportunities

Select Takeaways on Opportunity Set

22%
Of AMED Home Health Patients on Infusion Therapy²

340+
Markets OPCH Can Access³

38%
Overlap in Market Coverage for Value Capture³

Sources of Revenue Synergy

Opportunity Size



Complex & Chronic and Population Health Management



Cross-Selling Existing Services



Bundled Services for Medicare Advantage



Care Coordination Enhanced Services

Summary of Synergy Opportunity

- Ability to better manage costs for highly complex/chronic patients by ensuring continuity of care across settings
- Potential for growth in Value Based constructs moving forward
- Care transition specialists for combined company working directly with hospital discharge planners
- Targeting hospitals where either one or both organizations have had a relationship historically
- Potential to bundle certain services to more effectively manage patients in post-acute and preventative & chronic care settings
- Coordinate care for patients across (1) planned surgical procedures, (2) treatments for specific conditions, and (3) broader post-acute setting

Annualized Run-F Revenue Impact

+\$250M

Additional Potential Synergies Identified



Chronic Infusion Capture from Existing Amedisys Business



Revenue Cycle Optimization



Geographic Expansion



Naven Health Enablement



¹ Annualized run rate revenue impact by Year 3, related to the \$25M in expected revenue synergies. ² Based on 2022 Amedisys patient data. ³ Marwood Analysis, 2023.



option care health®

Mike Shapiro
Chief Financial Officer
(312) 940-2538
investor.relations@optioncare.com



amedisys

Nick Muscato
Chief Strategy Officer
(855) 259-2046
IR@amedisys.com

